These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 23617715)
1. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker. Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715 [TBL] [Abstract][Full Text] [Related]
2. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503 [TBL] [Abstract][Full Text] [Related]
3. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
4. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653 [TBL] [Abstract][Full Text] [Related]
5. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer. Wang L; Hong R; Shi S; Wang S; Chen Y; Han C; Li M; Ye F BMC Cancer; 2024 Aug; 24(1):1067. PubMed ID: 39210288 [TBL] [Abstract][Full Text] [Related]
7. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer. Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182 [TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor. Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697 [TBL] [Abstract][Full Text] [Related]
9. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294 [TBL] [Abstract][Full Text] [Related]
10. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Hayashi N; Nakamura S; Tokuda Y; Shimoda Y; Yagata H; Yoshida A; Ota H; Hortobagyi GN; Cristofanilli M; Ueno NT Int J Clin Oncol; 2012 Apr; 17(2):96-104. PubMed ID: 21671160 [TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
14. Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. Yap YS; Leong MC; Chua YW; Loh KWJ; Lee GE; Lim EH; Dent R; Ng RCH; Lim JH; Singh G; Tan A; Guan G; Wu A; Lee YF; Bhagat AAS; Lim DW PLoS One; 2019; 14(9):e0221305. PubMed ID: 31553731 [TBL] [Abstract][Full Text] [Related]
15. HER2-targeted therapy influences CTC status in metastatic breast cancer. Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146 [TBL] [Abstract][Full Text] [Related]
16. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Pierga JY; Hajage D; Bachelot T; Delaloge S; Brain E; Campone M; Diéras V; Rolland E; Mignot L; Mathiot C; Bidard FC Ann Oncol; 2012 Mar; 23(3):618-624. PubMed ID: 21642515 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Galardi F; De Luca F; Biagioni C; Migliaccio I; Curigliano G; Minisini AM; Bonechi M; Moretti E; Risi E; McCartney A; Benelli M; Romagnoli D; Cappadona S; Gabellini S; Guarducci C; Conti V; Biganzoli L; Di Leo A; Malorni L Breast Cancer Res; 2021 Mar; 23(1):38. PubMed ID: 33761970 [TBL] [Abstract][Full Text] [Related]
18. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer]. Li Y; Peng Z; Zhang X; Gong J; Shen L Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102 [TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. Müller V; Banys-Paluchowski M; Friedl TWP; Fasching PA; Schneeweiss A; Hartkopf A; Wallwiener D; Rack B; Meier-Stiegen F; Huober J; Rübner M; Hoffmann O; Müller L; Janni W; Wimberger P; Jäger B; Pantel K; Riethdorf S; Harbeck N; Fehm T; ESMO Open; 2021 Dec; 6(6):100299. PubMed ID: 34839105 [TBL] [Abstract][Full Text] [Related]
20. Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. Wallwiener M; Riethdorf S; Hartkopf AD; Modugno C; Nees J; Madhavan D; Sprick MR; Schott S; Domschke C; Baccelli I; Schönfisch B; Burwinkel B; Marmé F; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2014 Jul; 14():512. PubMed ID: 25015676 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]